1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$85.67bn
- HK$90.92bn
- CNY31.83bn
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Sino Biopharmaceutical buys drugmaker Hangzhou Hygieia Biomedical for up to $172 million
Brief: Sino Biopharmaceutical Announces Acquisition Of 100% Equity Interest In Hygieia
Brief: Sino Biopharmaceutical Says Culmerciclib Capsule Approved By NMPA For Marketing
Brief: Sino Biopharmaceutical Says Tqf3250 Clinical Trial Approved By NMPA And FDA
Brief: Sino Biopharmaceutical Says Rotigotine Patch Approved For Marketing In China
Brief: Sino Biopharmaceutical Says LM-350 CDH17 Antibody-Drug Conjugate Receives Clinical Trial Approval From China's NMPA
Brief: Sino Biopharmaceutical Says TQB2102 Included In Breakthrough Therapeutic Designation Process In China
Brief: Sino Biopharmaceutical Says IND Application For TQF3250 Accepted By NMPA
Hansoh leads slide in HK-listed biotech shares on report of US curbs
Brief: Sino Biopharmaceutical Says Her2-Selective TKI Granted Breakthrough Therapeutic Designation
Brief: Sino Biopharmaceutical LM-302 Included In Breakthrough Therapeutic Designation Process By China's NMPA
Brief: Sino Biopharmaceutical Declares Interim Dividend Of HK5 Cents Per Share
Brief: Sino Biopharmaceutical Says China's NMPA Accepts Clinical Trial Application For TQB3142 "BCL-XL Protac"
Brief: Sino Biopharmaceutical Says Application For Clinical Trial Of TQB3122 Accepted By NMPA
Brief: Sino Biopharmaceutical Says Application For Phase II Clinical Trial On LM-24C5 "CEACAM5/4-1BB Bispecific Antibody" Approved By China NMPA
Brief: Sino Biopharmaceutical's Rovadicitinib Tablet Included In Breakthrough Therapeutic Designation